2016 Hematological Malignancies

HD11: Long-term Outcome

PFS ABVD

PFS BEACOPP base

10 year estimate [95%-CI] Hazard Ratio [95%-CI]

10 year estimate [95%-CI] Hazard Ratio [95%-CI]

ABVD+30Gy ABVD+20Gy Difference

83.9% [79.4% to 88.3%] 75.6% [70.3% to 80.9%] -8.3% [-15.2% to -1.3%]

BEAbase+30Gy 84.0% [79.6% to 88.4%] BEAbase+20Gy 83.7% [79.2% to 88.3%] -0.3% [-6.6% to 6.0%] Median observation time 108 months Difference

1.5 [1.0 to 2.1]

1.0 [0.7 to 1.5]

332

343

315

332

Median observation time 105 months

OS

10 year estimate [95%-CI] Hazard Ratio [95%-CI]

ABVD+30Gy ABVD+20Gy

356 90.9% [87.5% to 94.2%] 89.5% [86.1% to 93.0%]

 Inferior 10-year PFS with 20Gy IF-RT instead of 30Gy after 4x ABVD  No difference after 4x BEACOPP base  No difference regarding 10-year OS

350

1.2 [0.7 to 1.9] 1.0 [0.6 to 1.7] 1.0 [0.6 to 1.7]

BEAbase+30Gy 90.5% [87.2% to 93.9%] BEAbase+20Gy 91.4% [88.2% to 94.7%] Median observation time 117 months